REFERENCES
- El-Kaissi S, Bowden J, Henry MJ, et al. Association between radioiodine therapy for Graves’ hyperthyroidism and thyroid-associated ophthalmopathy. Int Ophthalmol 2010;30(4):397–405
- Douglas RS, Gupta S. The pathophysiology of TED: Implications for immunotherapy. Curr Opin Ophthalmol 2011;22(5):385–390
- El-Kaissi S, Frauman AG, Wall JR. Thyroid-associated ophthalmopathy: A practical guide to classification, natural history and management. Intern Med J 2004;34:482–491
- Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: Reality and perspectives. Endocr Rev 2000;21:168–199
- Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73–78
- Tallstedt L, Lundell G, Tørring O, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med 1992;326:1733–1738
- Träisk F, Tallstedt L, Abraham-Nordling, et al. Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009;94:3700–3707
- Bartalena L. Glucocorticoids for Graves’ ophthalmopathy: How and when. J Clin Endocrinol Metab 2005;90:5497–5499
- Perros P, Kendall-Taylor P, Neoh C, et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J Clin Endocrinol Metab 2005;90:5321–5323
- Lai A, Sassi L, Compri E, et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves’ orbitopathy: A retrospective cohort study. J Clin Endocrinol Metab 2010;95:1–5
- Bartalena L, Bogazzi F, Tanda ML, et al. Cigarette smoking and the thyroid. Eur J Endocrinol 1995;133:507–12
- Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Grave’s ophthalmopathy. Ann Intern Med 1998;129:632–635
- Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006;91(9):3464–3470
- Vannucchi G, Campi I, Covelli D, et al. Graves’ orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab 2009;94(9):3381–3386